AIRLINK 195.65 Increased By ▲ 3.81 (1.99%)
BOP 10.16 Increased By ▲ 0.29 (2.94%)
CNERGY 7.87 Increased By ▲ 0.20 (2.61%)
FCCL 38.31 Increased By ▲ 0.45 (1.19%)
FFL 16.07 Increased By ▲ 0.31 (1.97%)
FLYNG 25.41 Increased By ▲ 0.10 (0.4%)
HUBC 130.75 Increased By ▲ 0.58 (0.45%)
HUMNL 13.94 Increased By ▲ 0.35 (2.58%)
KEL 4.66 Decreased By ▼ -0.01 (-0.21%)
KOSM 6.31 Increased By ▲ 0.10 (1.61%)
MLCF 45.13 Increased By ▲ 0.84 (1.9%)
OGDC 209.27 Increased By ▲ 2.40 (1.16%)
PACE 6.67 Increased By ▲ 0.11 (1.68%)
PAEL 41.20 Increased By ▲ 0.65 (1.6%)
PIAHCLA 17.67 Increased By ▲ 0.08 (0.45%)
PIBTL 8.15 Increased By ▲ 0.08 (0.99%)
POWER 9.36 Increased By ▲ 0.12 (1.3%)
PPL 180.80 Increased By ▲ 2.24 (1.25%)
PRL 39.80 Increased By ▲ 0.72 (1.84%)
PTC 24.58 Increased By ▲ 0.44 (1.82%)
SEARL 110.70 Increased By ▲ 2.85 (2.64%)
SILK 0.98 Increased By ▲ 0.01 (1.03%)
SSGC 38.40 Decreased By ▼ -0.71 (-1.82%)
SYM 19.30 Increased By ▲ 0.18 (0.94%)
TELE 8.79 Increased By ▲ 0.19 (2.21%)
TPLP 12.33 Decreased By ▼ -0.04 (-0.32%)
TRG 66.10 Increased By ▲ 0.09 (0.14%)
WAVESAPP 12.45 Decreased By ▼ -0.33 (-2.58%)
WTL 1.70 No Change ▼ 0.00 (0%)
YOUW 3.97 Increased By ▲ 0.02 (0.51%)
BR100 12,074 Increased By 143.5 (1.2%)
BR30 36,019 Increased By 359.3 (1.01%)
KSE100 114,864 Increased By 1657.7 (1.46%)
KSE30 36,096 Increased By 531 (1.49%)

LONDON: Britain will start rolling out Pfizer's COVID-19 pill to vulnerable people next month, the health ministry said on Friday, targeting the treatment at people with compromised immune systems for whom the vaccine can be less effective.

The health ministry said that Pfizer's antiviral treatment Paxlovid, a combination of Pfizer's pill with an older antiviral ritonavir, will be made available to thousands of people from Feb. 10.

"It is fantastic news that this new treatment, the latest cutting-edge drug that the NHS is rolling out through new COVID-19 medicine delivery units, will now be available to help those at highest risk of COVID-19," National Health Service medical director Stephen Powis said.

Britain approves Pfizer's antiviral COVID-19 pill

"Trials have shown it can reduce hospitalisation and risk of death by 88%, meaning we'll be in the best position to save thousands of lives."

Britain has ordered 2.75 million courses of Paxlovid, and the government said that it would set out further details on access to the treatment soon but that people who are immunocompromised, cancer patients or those with Down's Syndrome could be able to access it directly.

Merck's COVID-19 pill active against Omicron in lab studies

It is the second antiviral being rolled out in Britain after molnupiravir, a pill made by Merck and Ridgeback Biotherapeutics which is being deployed to patients through the Panoramic trial.

Comments

Comments are closed.